Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

<p>amino acid sequences of mAbs in this study</p>

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Yuncheng Bei (16546095) (author)
Eará dahkkit:	Jian He (16546098) (author), Xuhui Dong (16546101) (author), Yuxin Wang (16546104) (author), Sijie Wang (16546107) (author), Wan Guo (16546110) (author), Chengjie Cai (16546113) (author), Zhiye Xu (16546116) (author), Jia Wei (11469308) (author), Baorui Liu (15134681) (author), Nan Zhang (16546119) (author), Pingping Shen (16546122) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Therapeutic Research and Development Methods and Technology Biological Agents & Therapies Antibody-drug conjugates Computational Methods Database resources Drug Targets Cell surface receptor drug targets Preclinical Models Xenograft models
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Dahkki: Yuncheng Bei (16546095)
Almmustuhtton: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Dahkki: Yuncheng Bei (16546095)
Almmustuhtton: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Dahkki: Sheheryar Kabraji (15050565)
Almmustuhtton: (2025)

Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Dahkki: Amr El Zawily (14851115)
Almmustuhtton: (2025)

Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Dahkki: Amr El Zawily (14851115)
Almmustuhtton: (2025)

Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Dahkki: Amr El Zawily (14851115)
Almmustuhtton: (2025)

Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Dahkki: Amr El Zawily (14851115)
Almmustuhtton: (2025)

Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Dahkki: Amr El Zawily (14851115)
Almmustuhtton: (2025)

Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Dahkki: Amr El Zawily (14851115)
Almmustuhtton: (2025)

Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Dahkki: Amr El Zawily (14851115)
Almmustuhtton: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Dahkki: Martina S.J. McDermott (15206951)
Almmustuhtton: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Dahkki: Martina S.J. McDermott (15206951)
Almmustuhtton: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Dahkki: Martina S.J. McDermott (15206951)
Almmustuhtton: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Dahkki: Martina S.J. McDermott (15206951)
Almmustuhtton: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Dahkki: Martina S.J. McDermott (15206951)
Almmustuhtton: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Dahkki: Martina S.J. McDermott (15206951)
Almmustuhtton: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Dahkki: Martina S.J. McDermott (15206951)
Almmustuhtton: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Dahkki: Martina S.J. McDermott (15206951)
Almmustuhtton: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Dahkki: Martina S.J. McDermott (15206951)
Almmustuhtton: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
Dahkki: Santiago Duro-Sánchez (14959182)
Almmustuhtton: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Dahkki: Erwin Tomasich (15052256)
Almmustuhtton: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Dahkki: Erwin Tomasich (15052256)
Almmustuhtton: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Dahkki: Erwin Tomasich (15052256)
Almmustuhtton: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Dahkki: Erwin Tomasich (15052256)
Almmustuhtton: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Dahkki: Erwin Tomasich (15052256)
Almmustuhtton: (2025)

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Dahkki: Erwin Tomasich (15052256)
Almmustuhtton: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Dahkki: Xiaoqing Cheng (16918496)
Almmustuhtton: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Dahkki: Xiaoqing Cheng (16918496)
Almmustuhtton: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Dahkki: Xiaoqing Cheng (16918496)
Almmustuhtton: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Dahkki: Xiaoqing Cheng (16918496)
Almmustuhtton: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Dahkki: Xiaoqing Cheng (16918496)
Almmustuhtton: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Dahkki: Xiaoqing Cheng (16918496)
Almmustuhtton: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Dahkki: Niklas Klümper (15048887)
Almmustuhtton: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Dahkki: Niklas Klümper (15048887)
Almmustuhtton: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Dahkki: Yuanqing Ma (15052437)
Almmustuhtton: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Dahkki: Yuanqing Ma (15052437)
Almmustuhtton: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Dahkki: Yuanqing Ma (15052437)
Almmustuhtton: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Dahkki: Yuanqing Ma (15052437)
Almmustuhtton: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Dahkki: Yuanqing Ma (15052437)
Almmustuhtton: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Dahkki: Yuanqing Ma (15052437)
Almmustuhtton: (2025)

Cannot write session to /tmp/vufind_sessions/sess_qv3hb6cb30910pdt0rs7f6vgdt